This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies | MicrobiomeTrials
← Back to trials NCT05885555
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2023-08-16Est. Completion: 2025-02-05
Enrollment target: 41 participantsLocations Massachusetts General Hospital, Boston, Massachusetts, United States Beth Israel Deaconess Med Center, Boston, Massachusetts, United States Novartis Investigative Site, CABA, Argentina Novartis Investigative Site, Garran, Australian Capital Territory, Australia Novartis Investigative Site, Melbourne, Victoria, Australia Novartis Investigative Site, Wuhan, Hubei, China Novartis Investigative Site, Beijing, China Novartis Investigative Site, Jinan, China Novartis Investigative Site, Toulouse, France Novartis Investigative Site, Dresden, Saxony, Germany Novartis Investigative Site, Jena, Thuringia, Germany Novartis Investigative Site, Giessen, Germany Novartis Investigative Site, Torino, TO, Italy Novartis Investigative Site, Johor Bahru, Malaysia Novartis Investigative Site, Katowice, Poland Novartis Investigative Site, Seoul, South Korea Novartis Investigative Site, Barcelona, Catalonia, Spain Novartis Investigative Site, Aydin, Efeler, Turkey (Türkiye) Other microbiome trials you might be interested in Chronic Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult pat…
Los Angeles, United States Est. completion Dec 2026
Immune Thrombocytopenia (ITP)
Primary Objective: To evaluate the safety and efficacy of CHT105 Injection in subjects with relapsed/refractory autoimmu…
Nanchang, China Est. completion Dec 2027
Novartis Investigative Site, Istanbul, Fatih, Turkey (Türkiye)
Novartis Investigative Site, Edirne, Merkez, Turkey (Türkiye)
Novartis Investigative Site, Izmir, Turkey (Türkiye)
Novartis Investigative Site, Kocaeli, Turkey (Türkiye)
Novartis Investigative Site, Glasgow, United Kingdom
Novartis Investigative Site, London, United Kingdom